AmyriAD is developing Ismidenon, a novel, once-daily oral small molecule therapy designed to improve cognition and independent global function in patients with Alzheimer’s disease (AD).
AmyriAD is advancing next-generation therapies to improve cognition and function in Alzheimer’s disease.
Our leadership has a legacy of success in AD drug development that remains unsurpassed.
Alzheimer’s is a complex disease—devastating for patients and families alike.
Alzheimer’s Disease (AD) wreaks havoc on our loved ones in painfully intimate ways, disrupting memory, identity, and connection. At its core: abnormal protein buildup, chronic neuroinflammation, and a breakdown in cholinergic signaling driven by acetylcholine deficits.
Over three decades of research has shown that addressing the acetylcholine (ACh) deficiency is essential for improving the core symptoms of AD, such as cognitive function and memory loss. However, realizing the full potential of this therapeutic strategy has been constrained by safety concerns and adverse effects associated with cholinesterase inhibitors, particularly their impact on peripheral neuronal tissue.
Amyriad therapeutics is exploring a multi-modal approach to acetylcholine stimulation which promises to enhance cognitive function and memory while minimizing peripheral side effects.
OUR LEAD THERAPEUTIC CANDIDATE,
ISMIDENON IS IN PREPARATION FOR A PHASE 2/3 REGISTRATION TRIAL IN THE US
Our efforts are focused on improving global function and cognition, the two key areas affected by AD.
Our lead compound, Ismidenon, is a small, synthetic molecule that enhances cholinergic tone in patients already on donepezil.
* Ismidenon was formerly designated as AD101